

Masashi Narazaki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5083126/publications.pdf>

Version: 2024-02-01

89
papers

11,572
citations

53751

45
h-index

56687

83
g-index

89
all docs

89
docs citations

89
times ranked

16131
citing authors

#	ARTICLE	IF	CITATIONS
1	IL-6 in Inflammation, Immunity, and Disease. Cold Spring Harbor Perspectives in Biology, 2014, 6, a016295-a016295.	2.3	2,943
2	Structure and function of a new STAT-induced STAT inhibitor. Nature, 1997, 387, 924-929.	13.7	1,224
3	Targeting Interleukin-6 Signaling in Clinic. Immunity, 2019, 50, 1007-1023.	6.6	570
4	Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy, 2016, 8, 959-970.	1.0	521
5	Dysbiosis Contributes to Arthritis Development via Activation of Autoreactive T Cells in the Intestine. Arthritis and Rheumatology, 2016, 68, 2646-2661.	2.9	463
6	Cardiotrophin-1 Activates a Distinct Form of Cardiac Muscle Cell Hypertrophy. Journal of Biological Chemistry, 1996, 271, 9535-9545.	1.6	344
7	Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT) Tj ETQq1 1 0.784314 rgBT /Overl America, 1998, 95, 15577-15582.	3.3	272
8	Therapeutic Targeting of the Interleukin-6 Receptor. Annual Review of Pharmacology and Toxicology, 2012, 52, 199-219.	4.2	240
9	Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 13130-13134.	3.3	226
10	Interleukin (IL-6) Immunotherapy. Cold Spring Harbor Perspectives in Biology, 2018, 10, a028456.	2.3	223
11	Functional inhibition of hematopoietic and neurotrophic cytokines by blocking the interleukin 6 signal transducer gp130. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 10998-11001.	3.3	197
12	Differential processing of stromal-derived factor-1 α and stromal-derived factor-1 β explains functional diversity. Blood, 2004, 103, 2452-2459.	0.6	192
13	Signals transducers and activators of transcription (STAT)-induced STAT inhibitor-1 (SSI-1)/suppressor of cytokine signaling-1 (SOCS-1) suppresses tumor necrosis factor alpha -induced cell death in fibroblasts. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 5405-5410.	3.3	179
14	The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology, 2010, 49, 2408-2412.	0.9	177
15	SOCS-1/SSI-1-Deficient NKT Cells Participate in Severe Hepatitis through Dysregulated Cross-Talk Inhibition of IFN- β and IL-4 Signaling In Vivo. Immunity, 2001, 14, 535-545.	6.6	176
16	The role and therapeutic targeting of IL-6 in rheumatoid arthritis. Expert Review of Clinical Immunology, 2017, 13, 535-551.	1.3	166
17	Cloning and Functional Analysis of New Members of STAT Induced STAT Inhibitor (SSI) Family: SSI-2 and SSI-3. Biochemical and Biophysical Research Communications, 1997, 237, 79-83.	1.0	164
18	Apoptosis-derived membrane vesicles drive the cGAS \rightarrow STING pathway and enhance type I IFN production in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2018, 77, 1507-1515.	0.5	164

#	ARTICLE	IF	CITATIONS
19	Sialylation converts arthritogenic IgG into inhibitors of collagen-induced arthritis. <i>Nature Communications</i> , 2016, 7, 11205.	5.8	148
20	Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 103-111.	0.5	145
21	A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. <i>Seminars in Immunology</i> , 2014, 26, 88-96.	2.7	144
22	The Two-Faced Cytokine IL-6 in Host Defense and Diseases. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3528.	1.8	143
23	Signal Transducer and Activator of Transcription (Stat)-Induced Stat Inhibitor 1 (Ssi-1)/Suppressor of Cytokine Signaling 1 (Socs1) Inhibits Insulin Signal Transduction Pathway through Modulating Insulin Receptor Substrate 1 (Irs-1) Phosphorylation. <i>Journal of Experimental Medicine</i> , 2001, 193, 263-270.	4.2	138
24	Regulation of IL-6 in Immunity and Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2016, 941, 79-88.	0.8	135
25	Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. <i>FEBS Letters</i> , 2011, 585, 3699-3709.	1.3	123
26	Therapeutic effect of tocilizumab on two patients with polymyositis. <i>Rheumatology</i> , 2011, 50, 1344-1346.	0.9	115
27	Historical overview of the interleukin-6 family cytokine. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	115
28	A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. <i>Modern Rheumatology</i> , 2012, 22, 298-302.	0.9	97
29	Identification of carboxypeptidase N as an enzyme responsible for C-terminal cleavage of stromal cell-derived factor-1 α in the circulation. <i>Blood</i> , 2005, 105, 4561-4568.	0.6	93
30	IFN Regulatory Factor-1-Mediated Transcriptional Activation of Mouse STAT-Induced STAT Inhibitor-1 Gene Promoter by IFN- β . <i>Journal of Immunology</i> , 2000, 164, 5833-5843.	0.4	83
31	Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab: Figure 1. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1164-1165.	0.5	79
32	Semaphorin 4D Contributes to Rheumatoid Arthritis by Inducing Inflammatory Cytokine Production: Pathogenic and Therapeutic Implications. <i>Arthritis and Rheumatology</i> , 2015, 67, 1481-1490.	2.9	79
33	Fungal ITS1 Deep-Sequencing Strategies to Reconstruct the Composition of a 26-Species Community and Evaluation of the Gut Mycobiota of Healthy Japanese Individuals. <i>Frontiers in Microbiology</i> , 2017, 8, 238.	1.5	79
34	Ligand-induced internalization selects use of common receptor neuropilin-1 by VEGF165 and semaphorin3A. <i>Blood</i> , 2006, 107, 3892-3901.	0.6	74
35	Defective Thymocyte Development and Perturbed Homeostasis of T cells in STAT-Induced STAT Inhibitor-1/Suppressors of Cytokine Signaling-1 Transgenic Mice. <i>Journal of Immunology</i> , 2000, 165, 1799-1806.	0.4	73
36	Leptin receptor (OB-R) oligomerizes with itself but not with its closely related cytokine signal transducer gp130. <i>FEBS Letters</i> , 1997, 403, 79-82.	1.3	72

#	ARTICLE	IF	CITATIONS
37	Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1235-1236.	0.5	72
38	Association of recombinant soluble IL-6-signal transducer, gp130, with a complex of IL 6 and soluble IL-6 receptor, and establishment of an ELISA for soluble gp130. <i>Immunology Letters</i> , 1992, 31, 123-130.	1.1	70
39	Tocilizumab for the treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2010, 6, 843-854.	1.3	70
40	Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. <i>Arthritis and Rheumatism</i> , 2009, 61, 1762-1764.	6.7	69
41	Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpesvirus. <i>Blood</i> , 2001, 98, 3042-3049.	0.6	68
42	A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. <i>Modern Rheumatology</i> , 2012, 22, 298-302.	0.9	64
43	Semaphorin 4D inhibits neutrophil activation and is involved in the pathogenesis of neutrophil-mediated autoimmune vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1440-1448.	0.5	57
44	Regulation of intestinal homeostasis by the ulcerative colitis-associated gene RNF186. <i>Mucosal Immunology</i> , 2017, 10, 446-459.	2.7	55
45	Sulfated polysaccharides identified as inducers of neuropilin-1 internalization and functional inhibition of VEGF165 and semaphorin3A. <i>Blood</i> , 2008, 111, 4126-4136.	0.6	51
46	Overlapping and distinct signals through leptin receptor (OB-R) and a closely related cytokine signal transducer, gp130. <i>FEBS Letters</i> , 1997, 401, 49-52.	1.3	44
47	Effect of Enzymatically Modified Isoquercitrin, a Flavonoid, on Symptoms of Japanese Cedar Pollinosis: A Randomized Double-Blind Placebo-Controlled Trial. <i>International Archives of Allergy and Immunology</i> , 2009, 149, 359-368.	0.9	41
48	Preventative Effect of a Flavonoid, Enzymatically Modified Isoquercitrin on Ocular Symptoms of Japanese Cedar Pollinosis. <i>Allergology International</i> , 2009, 58, 373-382.	1.4	40
49	Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2013, 42, 253-259.	0.6	33
50	The COMMD3/8 complex determines GRK6 specificity for chemoattractant receptors. <i>Journal of Experimental Medicine</i> , 2019, 216, 1630-1647.	4.2	32
51	The Molecular Biology of Interleukin 6 and its Receptor. <i>Novartis Foundation Symposium</i> , 1992, 167, 5-23.	1.2	32
52	Vav is associated with signal transducing molecules gp130, Grb2 and Erk2, and is tyrosine phosphorylated in response to interleukin-6. <i>FEBS Letters</i> , 1997, 401, 133-137.	1.3	31
53	Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab. <i>Modern Rheumatology</i> , 2015, 25, 134-137.	0.9	26
54	LRRK1 is critical in the regulation of B-cell responses and CARMA1-dependent NF- κ B activation. <i>Scientific Reports</i> , 2016, 6, 25738.	1.6	26

#	ARTICLE	IF	CITATIONS
55	Minimal influence of tocilizumab on IFN- \hat{I}^3 synthesis by tuberculosis antigens. <i>Modern Rheumatology</i> , 2010, 20, 130-133.	0.9	25
56	Clonal evolution and antigen recognition of anti-nuclear antibodies in acute systemic lupus erythematosus. <i>Scientific Reports</i> , 2017, 7, 16428.	1.6	24
57	Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody, tocilizumab. <i>Rheumatology</i> , 2010, 49, 824-826.	0.9	21
58	Minimal influence of tocilizumab on IFN- \hat{I}^3 synthesis by tuberculosis antigens. <i>Modern Rheumatology</i> , 2010, 20, 130-133.	0.9	20
59	Viral Interleukin 6 Stimulates Human Peripheral Blood B Cells That Are Unresponsive to Human Interleukin 6. <i>Cellular Immunology</i> , 2001, 212, 118-125.	1.4	19
60	Targeting Coagulation to the Tumor Microvasculature: Perspectives and Therapeutic Implications From Preclinical Studies. <i>Journal of the National Cancer Institute</i> , 2005, 97, 705-707.	3.0	16
61	Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway. <i>Modern Rheumatology</i> , 2009, 19, 522-529.	0.9	16
62	Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab. <i>Modern Rheumatology</i> , 2011, 21, 420-422.	0.9	15
63	Etanercept improved primary biliary cirrhosis associated with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2009, 76, 105-107.	0.8	13
64	Interleukin-6; pathogenesis and treatment of autoimmune inflammatory diseases. <i>Inflammation and Regeneration</i> , 2013, 33, 054-065.	1.5	13
65	Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab. <i>Modern Rheumatology</i> , 2013, , 1.	0.9	12
66	Tocilizumab: An Updated Review of Its Use in the Treatment of Rheumatoid Arthritis and Its Application for Other Immune-Mediated Diseases. <i>Clinical Medicine Insights Therapeutics</i> , 2013, 5, CMT.S9282.	0.4	12
67	Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab. <i>Modern Rheumatology</i> , 2011, 21, 420-422.	0.9	12
68	Tumor Cell Populations Differ in Angiogenic Activity: A Model System for Spontaneous Angiogenic Switch Can Tell Us Why. <i>Journal of the National Cancer Institute</i> , 2006, 98, 294-295.	3.0	11
69	Increased levels of plasma nucleotides in patients with rheumatoid arthritis. <i>International Immunology</i> , 2021, 33, 119-124.	1.8	11
70	Tet DNA demethylase is required for plasma cell differentiation by controlling expression levels of IRF4. <i>International Immunology</i> , 2020, 32, 683-690.	1.8	10
71	Current status and prospects of IL-6 targeting therapy. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 575-592.	1.3	10
72	Neuropilin-2: A New Molecular Target for Antiangiogenic and Antitumor Strategies. <i>Journal of the National Cancer Institute</i> , 2008, 100, 81-83.	3.0	9

#	ARTICLE	IF	CITATIONS
73	Anti-receptor activator of nuclear factor κ B ligand antibody treatment increases osteoclastogenesis-promoting IL-8 in patients with rheumatoid arthritis. <i>International Immunology</i> , 2019, 31, 277-285.	1.8	9
74	Loss of FCHSD1 leads to amelioration of chronic obstructive pulmonary disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	7
75	Oligo-guanosine nucleotide induces neuropilin-1 internalization in endothelial cells and inhibits angiogenesis. <i>Blood</i> , 2010, 116, 3099-3107.	0.6	6
76	What kind of durometer is best suited for the assessment of skin disease in systemic sclerosis? Comment on the article by Kissin et al. <i>Arthritis and Rheumatism</i> , 2008, 59, 601-601.	6.7	4
77	Recovery from prolonged thrombocytopenia in patients with TAFRO syndrome: case series and literature review. <i>Modern Rheumatology Case Reports</i> , 2020, 4, 302-309.	0.3	4
78	Therapeutic Implications of Tocilizumab, A Humanized Anti-Interleukin-6 Receptor Antibody, for Various Immune-Mediated Diseases: An Update Review. <i>Current Rheumatology Reviews</i> , 2012, 8, 209-226.	0.4	4
79	Canstatin: an inhibitor of angiogenesis and tumor growth revisited. <i>Cancer Journal (Sudbury, Mass)</i> , 2006, 12, 110-2.	1.0	4
80	Immune reconstitution inflammatory syndrome in a patient with adult-onset Still's disease: Graft-versus-host-like skin reaction with possible asymptomatic human herpes virus reactivation during steroid tapering. <i>European Journal of Dermatology</i> , 2014, 24, 101-103.	0.3	2
81	IL-6 Superfamily. , 2017, , 573-586.		2
82	Conflicting Results from Clinical Observations and Murine Models: What Is the Role of Plasminogen Activators in Tumor Growth?. <i>Journal of the National Cancer Institute</i> , 2006, 98, 726-727.	3.0	1
83	Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for the treatment of autoimmune disorders. <i>Drug Development Research</i> , 2011, 72, 717-732.	1.4	1
84	Interleukin-6 Inhibition in Inflammatory Diseases: Results Achieved and Tasks to Accomplish. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, S20-S28.	1.0	1
85	Pulmonary artery hypertension prior to the relapse of adult-onset Still's disease. <i>Respirology Case Reports</i> , 2021, 9, e00746.	0.3	1
86	Effect of Enzymatically Modified Isoquercitrin, a Flavonoid, on Symptoms of Japanese Cedar Pollinosis. <i>World Allergy Organization Journal</i> , 2012, 5, S181.	1.6	0
87	Anti-Interleukin-6 Receptor Antibody Therapy Against Autoimmune Inflammatory Diseases. , 2015, , 515-525.		0
88	A case of SAPHO syndrome with the lesions limited to the skull. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa034.	0.3	0
89	Negative-feedback Regulations Of Cytokine Signals. , 2000, , .		0